Trial reportBlood2017
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Erratum issuedAbstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Trial
- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.The Lancet. Haematology · 2019Trial
- Trial
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.European journal of haematology · 2026Article
- Article
- Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.HemaSphere · 2025Article
- Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.American journal of hematology · 2025Review
- Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.Discover oncology · 2024Review
- Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When.Cancers · 2023Review
- A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.PharmacoEconomics - open · 2023Article
- Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.Leukemia & lymphoma · 2022Article
- Review
- Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.Leukemia · 2021Review
- Article
- Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.Medicine · 2021Article
- Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.Frontiers in oncology · 2021Article
- Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme.Frontiers in genetics · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
27 authors.
Kirsten FischerDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Othman Al-SawafDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Anna-Maria FinkDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Mark DixonF. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Jasmin BahloDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Simon WarburtonF. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Thomas J KippsMoores Cancer Center, University of California San Diego, San Diego, CA.
Robert WeinkoveWellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
Sue RobinsonQueen Elizabeth II Health Science Center, Halifax, NS, Canada.
Till SeilerDepartment of Internal Medicine III, University Hospital Ludwig-Maximilians University Munich, Munich, Germany.
Stephen OpatMonash Hematology, Monash University, Clayton, VIC, Australia.
Carolyn OwenDepartment of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada.
Javier LópezHospital Ramon y Cajal, Madrid, Spain.
Kathryn HumphreyF. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Rod HumerickhouseAbbVie, Inc., North Chicago, IL.
Eugen TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Lukas FrenzelDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Barbara EichhorstDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Clemens-M WendtnerDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Anton W LangerakDepartment of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
Jacque J M van DongenDepartment of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
Sebastian BöttcherSecond Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
Matthias RitgenSecond Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
Valentin GoedeDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Mehrdad MobasherGenentech, South San Francisco, CA.
Michael HallekDepartment I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedSulfonamidesAntibodies, Monoclonal, HumanizedBridged Bicyclo Compounds, HeterocyclicobinutuzumabSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.